A popular prescription anxiety drug is being recalled nationwide for a “possibly life-threatening” mistake on the carton.
The Pennsylvania-based drug maker Endo announced this week that it is expanding its recall of clonazepam tablets because some cartons bear the incorrect drug strength and wrong drug code.
The new recall affects 16 lots of Clonazepam Orally Disintegrating Tablets, USP (C-IV), with doses ranging from 0.125 milligrams to 2 milligrams. The packages feature 10 blister strips that each contain six tablets. They are due to expire between August 2026 and February 2027.
Clonazepam is a benzodiazepine used to treat panic disorder and certain types of seizures.
Endo warns that consuming a higher dose of clonazepam could increase the risk of sleepiness, confusion, dizziness, diminished reflexes and loss of muscle control or strength.
There’s also the risk of “significant, possibly life-threatening” breathing troubles, especially for those with respiratory disease, those being prescribed the maximum dose and those taking other medications that affect breathing.
Endo reports that as of Monday, it has not received any reports of problems stemming from the recall. The pharmaceutical company announced its initial recall in July of just one lot of clonazepam.
At the time, Endo blamed an “error at a third-party packager” for the mislabeling.
Some cartons showed the product strength as 0.125 mg and not 0.25 mg. The blister strips inside the package reflected the correct strength, Endo said.
The recalled cartons also list Par Pharmaceutical of New York as the distributor. The company, based in Chestnut Ridge, marketed clonazepam before the product was acquired by Endo.
People with questions about the recall should call (855) 589-1869 or email rxrecalls@inmar.com.
Retailers with these products are being directed not to sell them, while consumers shouldn’t take them. Consult a physician if you believe you took an incorrect dose of clonazepam.
